WO2016066050A1 - 可佩戴智能药物导入系统 - Google Patents

可佩戴智能药物导入系统 Download PDF

Info

Publication number
WO2016066050A1
WO2016066050A1 PCT/CN2015/092546 CN2015092546W WO2016066050A1 WO 2016066050 A1 WO2016066050 A1 WO 2016066050A1 CN 2015092546 W CN2015092546 W CN 2015092546W WO 2016066050 A1 WO2016066050 A1 WO 2016066050A1
Authority
WO
WIPO (PCT)
Prior art keywords
storage
electrode
opening
disposed
reservoir
Prior art date
Application number
PCT/CN2015/092546
Other languages
English (en)
French (fr)
Inventor
黄智礼
陈敬龙
Original Assignee
厦门微科格瑞生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 厦门微科格瑞生物科技有限公司 filed Critical 厦门微科格瑞生物科技有限公司
Priority to US15/312,182 priority Critical patent/US20170072184A1/en
Publication of WO2016066050A1 publication Critical patent/WO2016066050A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Definitions

  • the invention relates to a wearable smart drug introduction system.
  • Drugs provide a therapeutic effect on different diseases, usually must be administered at a certain time or in a certain time mode or must be maintained at a certain concentration level to achieve the best therapeutic effect.
  • patients usually do not take medication at the required intervals or time slots.
  • oral medications may cause partial or complete failure due to the high acidity environment of the stomach or the first-pass effect of the liver.
  • the drug can be administered through the skin.
  • a common method of parenteral administration is to inject different doses of the drug by syringe or continuous instillation. These methods may not be suitable for long-term treatment of patients, because repeated injuries and intravenous drip devices can limit the patient's freedom of movement and cause pain to the patient.
  • a more comfortable drug delivery device is administered via the epidermis.
  • the application of such plasters or plasters is extensive.
  • Administration by means of a patch is usually provided over a period of time (e.g., one day to one week), providing a continuous dose of administration without the patient's active request for administration.
  • the daily application of drugs suitable for dermal administration is: nicotine, hormones and some analgesics (such as fentanyl) and other pharmaceutical dosage forms, such as donepezil hydrochloride, aspirin, ibuprofen, Ritalin and the like.
  • Applications include nicotine patches for smoking cessation; patches for contraception by continuously releasing low levels of estrogen and progestogen to the skin.
  • This epidermal delivery device is portable, comfortable and well suited for patients who are afraid of needle sticking.
  • the main advantages of epidermal administration are: providing a sustained dose at the designed release rate; avoiding the effects of the first pass effect of the gastrointestinal tract and liver on oral medication; non-invasive; no patient intervention, but patients can also be administered at any time or Stop the drug.
  • Electro-ion osmosis therapy is a physical process in which ion flux is diffused by an external electric field medium, so that soluble ionic salt drugs enter the body under the action of electricity, thereby achieving therapeutic purposes.
  • the device for iontophoresis began as early as 1900.
  • a British patent (410,009) describes an iontophoresis device that is formed to include: a plurality of electrodes and a material containing a therapeutic component or drug that can be percutaneously penetrated, and an iontophoresis drug delivery device.
  • a battery that requires energy. The device is accepted because it reduces the effect of administration on the daily life of the patient, and is an early realization of iontophoresis. Recently, the U.S.
  • an iontophoresis device at least two electrodes are used, which are in direct contact with the skin, and a transdermal enhancer is used at the time of use, which is very damaging to the skin.
  • An electrode is called an active electrode that acts on a chemical substance, compound, agent, or drug by electricity to transport it or into the body.
  • the other is the counter electrode.
  • the most prominent advantage of iontophoresis is the control of drug delivery and time.
  • the technical problem to be solved by the present invention is to provide a wearable smart drug introduction system, which is convenient for the user to use.
  • a wearable smart drug introduction system comprising a sachet structure and a first power source, wherein the sachet structure is provided with a first repository and a second repository, the second The first storage is disposed in the ring of the second storage, the first storage is provided with a first electrode, and the first storage is provided with a first opening on one side thereof.
  • a first permeable membrane is disposed at the first opening, the first reservoir is filled with a gel-like medicinal solution, the second reservoir is provided with a second electrode, and the second reservoir is provided with a side surface a second opening, wherein the second opening is provided with a second release film, wherein the second reservoir is filled with a gel electrolyte, and the positive and negative electrodes of the first power source are respectively connected to the first electrode and Two electrodes.
  • first opening is opposite to the first electrode
  • second opening is opposite to the second electrode
  • the distance between the first repository and the second repository is greater than 10 mm.
  • first release film is disposed at the first opening
  • second release film is disposed at the second opening.
  • the gel-like drug is detachably disposed in the first storage
  • the gel electrolyte is detachably disposed in the second storage.
  • the method further includes at least one third storage, each of the third storage chambers being disposed in the first storage ring, and each of the third storages is provided with a third electrode, each of the a third opening is provided on one side of the third storage, and a third release film is disposed on the third opening, each of the third storages is filled with a gel-like liquid, and the first power source is connected to each The third electrode.
  • the third opening is opposite to the third electrode.
  • a wearable smart drug introduction system comprising a sachet structure and a first power source, wherein the sachet structure is provided with a first repository, a second repository and a central repository .
  • the second storage is annular, and the first storage is also annular, and is disposed between the second storage ring and the central storage.
  • a first electrode is disposed in the first storage, a first opening is disposed on a side of the first storage, the first storage is filled with a gel-like liquid; and the second storage is provided a second electrode, a second opening is disposed on a side of the second storage, the second storage is filled with a gel electrolyte, a central electrode is disposed in the central storage, and a side of the central storage A central opening is provided, the central storage is filled with a gel electrolyte, and the positive and negative electrodes of the first power source are respectively connected between the first electrode and the second electrode and the center electrode.
  • first permeable membrane is disposed at the first opening
  • second permeable membrane is disposed at the second opening
  • central permeable membrane is disposed at the central opening.
  • the first repository may be divided into at least one third repository, a third electrode is disposed in the third repository, and a third opening is disposed on a side of the third repository, the third A third translucent membrane is disposed at the opening, and the third reservoir is filled with a gel-like liquid.
  • the invention has the following advantages: the invention can wear the smart drug introduction system, and the dose and the conduction time of the ionization agent can be accurately and accurately controlled; the dose of the skin contact drug of the invention diffusing through the skin is much lower than the present invention; The dose of iontophoresis through the skin minimizes or avoids the uncontrolled dose of the drug percutaneous conduction; in the present invention, multiple drugs can be stored in one reservoir or in multiple reservoirs, and can be passed through one or more power sources. It is delivered to the body at the same time or at different times; and multiple drugs are stored in multiple reservoirs to avoid reaction and mutual interference between the drugs; it is also possible to reduce the skin irritation without using a transdermal enhancer.
  • FIG. 1 is a schematic structural view of Embodiment 1 of the present invention.
  • Figure 2 is a cross-sectional view showing a first embodiment of the present invention.
  • FIG. 3 is a schematic structural diagram of Embodiment 2 of the present invention.
  • FIG. 4 is a schematic structural view of a third embodiment of the present invention.
  • the invention can be used to wear a smart drug introduction system, comprising a sachet structure and a first power source, wherein the sachet structure is provided with a first storage reservoir and a second storage reservoir, the second storage reservoir is a ring shape, and the first storage is a first electrode is disposed in the first storage reservoir, a first opening is disposed on a side of the first storage, and a first opening is disposed in the first opening Release a film, the first reservoir is filled with a gel-like liquid, the second reservoir is provided with a second electrode, and a side of the second reservoir is provided with a second opening, the second opening Providing a second release film, the second reservoir is filled with a gel electrolyte, and the first and second electrodes are respectively connected to the first electrode and the second electrode, and the first opening and the The first electrode is opposite to the second electrode, and the second opening is opposite to the second electrode.
  • the distance between the first reservoir and the second reservoir is greater than 10 mm, and the gelled drug is detach
  • the present invention further includes at least one third storage, each of the third storage chambers being disposed in the first storage ring, and each of the third storages is provided with a third electrode, each of the a third opening is provided on one side of the three reservoirs, and a third translucent membrane is disposed at the third opening, each of the third reservoirs is filled with a gel-like liquid medicine, and the first power source is connected to each The third electrode is opposite to the third electrode.
  • Another embodiment of the invention includes at least a first repository, a second repository, and a central repository.
  • the second storage is annular, and the first storage is also annular, and is disposed between the second storage ring and the central storage.
  • a first electrode is disposed in the first storage, a first opening is disposed on a side of the first storage, a first release film is disposed on the first opening, and the first storage is filled with condensation a second liquid crystal is disposed in the second storage chamber, a second opening is disposed on one side of the second storage, and a second release film is disposed on the second opening, the second
  • the reservoir is filled with a gel electrolyte;
  • the central repository is provided with a central electrode, a central opening is provided on one side of the central storage, and a central translucent membrane is disposed at the central opening, the central repository
  • the electrolyte is filled with a gel electrolyte, and the positive and negative electrodes of the first power source are respectively connected between the first electrode and the second electrode and
  • the drug ions are transmitted to the skin through the above-mentioned release membrane, or may also be referred to as a permeable membrane, and a uniform pore having a certain pore diameter constitutes a membrane structure.
  • the wearable smart drug introduction system 100 of the present invention consists of a circular sachet structure 101 and a first power source (not shown) having a circular first reservoir 103 and a circular capsule structure 101.
  • the second storage reservoir 102 is formed.
  • the first storage 106 is provided with a first electrode 106.
  • the second storage 102 is provided with a second electrode 105.
  • the first electrode 106 and the second electrode are provided.
  • 105 is installed in the top wall of each storage, the bottom of the first storage 103 is provided with a first release film (not shown), and the bottom of the second storage 102 is provided with a second permeable release.
  • a film (not shown) may be used for the first electrode 106 in the first reservoir 103 and the second electrode 105 in the second reservoir 102.
  • the portion of the sachet structure 101 can be made of synthetic material or silicone rubber.
  • the size of the wearable smart drug introduction system 100 of the present invention is 75 mm in diameter and 6 mm in height, but other sizes are also available.
  • the first reservoir 103 has a diameter of 20 mm and a height of 3 mm.
  • the second reservoir 102 may have an inner diameter of 40 mm, an outer diameter of 45 mm, and a height of 3 mm, and other sizes may be used.
  • the bottom area of the second storage 102 and the first storage 103 is guaranteed to be the same as possible, and the distance L between the second storage 102 and the first storage 103 should be greater than 10 mm to ensure that the current can be evenly dispersed in the skin. on.
  • the gelled ionizing agent can be stored in the first reservoir 103.
  • the gel in the second reservoir 102 may be a gel containing only electrolytic ions.
  • the positive power terminal of the first power source is applied to the first electrode 106 in the first storage 103, and the negative power terminal of the first power source is applied to the second electrode 105 of the second storage 102.
  • the positively-charged ionizing agent in the first reservoir 103 is transferred from the first reservoir 103 through the first permeation membrane to the skin below it under the action of Coulomb force, and is transmitted to the body through the skin.
  • the ionized agent can be delivered to the body by dose by controlling the intensity of the output current or voltage of the first power source.
  • the positively ionized agent and the negatively ionized agent may be mixed with the gel matrix to form a gelled drug solution, which is stored in the first reservoir 103 or the second reservoir 102, respectively.
  • the reference gel matrix may be an organogel, a hydrogel, and in addition, hydroxyethylcellulose may be mixed with the gel matrix, but other gel matrices may also be used.
  • the positions corresponding to the first reservoir 102 and the second reservoir 103 may be a cavity structure.
  • the gel electrolyte and the gelled drug can be made into the size and shape of the corresponding cavity structure of the first reservoir 102 and the second reservoir 103, and the gel electrolyte and the gel drug can be placed therein. .
  • the gel-like electrolyte and the gel-like drug can be replaced, and the sachet structure device body 100 can be integrated into the wearable smart drug introduction device.
  • the wearable smart drug introduction system 210 of the present invention comprises a drug capsule structure device 211, a first power source (not shown), and a first repository 213. a third storage 214, a fourth storage 215 and a fifth storage 216, and a circular second storage 212.
  • the first storage 213 is provided with a first electrode (not shown) at the top.
  • a bottom of the storage 213 is provided with a first opening (not shown), a first permeable membrane (not shown) is disposed at the first opening, and a third electrode is disposed at the top of the third storage 214 (
  • the third storage 214 is provided with a third opening (not shown) at the bottom of the third storage 214, and a third permeable membrane (not shown) is disposed at the third opening;
  • the fourth storage 215 a fourth electrode (not shown) is disposed at the top, a fourth opening (not shown) is disposed at the bottom of the fourth storage 215, and a fourth permeable film is disposed at the fourth opening (not shown)
  • a fifth electrode (not shown) is disposed at the top of the fifth storage 216, and a fifth opening is provided at the bottom of the fifth storage 216 (not shown) a fifth permeable membrane (not shown) is disposed at the fifth opening;
  • a second electrode (not shown) is disposed at the top of the second reservoir 212, and the bottom of the
  • the smart drug introduction system 220 can be worn by the present invention, including a first power source (not shown), a first repository 223, and a third repository 224. a fourth repository 225 and a fifth repository 226, and a circular second repository 222 and a central repository 227, the first repository 223 is provided with a first electrode (not shown), first The bottom of the storage 223 is provided with a first opening (not shown), a first permeable membrane (not shown) is disposed at the first opening, and a third electrode is disposed at the top of the third storage 224 (Fig.
  • a third opening is disposed at the bottom of the third storage 224, and a third permeable membrane (not shown) is disposed at the third opening; the top of the fourth storage 225 a fourth electrode (not shown) is disposed on the bottom of the fourth reservoir 225, and a fourth opening (not shown) is disposed at the fourth opening.
  • a fifth electrode is disposed at the top of the fifth storage 226, and a fifth opening is provided at the bottom of the fifth storage 226 (not shown) a fifth permeable membrane (not shown) is disposed at the fifth opening;
  • a second electrode is disposed at the top of the second reservoir 222, and the bottom of the second reservoir 222 is provided with a second a second opening (not shown), wherein the second opening is provided with a second release film (not shown); in order to make the current more evenly distributed in the area under the wearable smart drug introduction system, wearable
  • the smart drug introduction system 220 further includes a central storage 227 having a center electrode (not shown) at the top of the central storage 227, and a sixth opening at the bottom of the central storage 227 (not shown) And a sixth translucent film (not shown) is disposed at the sixth opening.
  • the four agents can be placed in four reservoirs 223, 224, 225 and 226, respectively.
  • the third electrode of the second reservoir 222 is coupled to the center electrode of the central repository 227. Simultaneously applied between the electrodes of the first repository 223, the third repository 224, the fourth repository 225, and the fifth repository 226 by the first power source and the electrodes of the second repository 222 and the central repository 227 Transdermal administration of the medicament; or by a plurality of power sources respectively applied between the first reservoir 223 and the electrodes of the second reservoir 222 and the central repository 227, the third reservoir 224 and the second reservoir 222 and the center Between the electrodes of the reservoir 227, between the fourth reservoir 225 and the electrodes of the second reservoir 222 and the central repository 227, and between the fifth reservoir 226 and the electrodes of the second reservoir 222 and the central repository 227 To achieve transdermal administration of four agents at different times.
  • the third embodiment of the present invention may further include a second power source (not shown), a third power source (not shown), and a fourth power source (not shown), and the first power source is respectively connected to the first Between the electrode and the second electrode and the center electrode, that is, between the first reservoir 223 and the second reservoir 222 and the electrode of the central repository 227, the second power source is respectively connected to the third electrode and the second electrode and the center electrode.
  • the third power source is connected between the fourth electrode and the second electrode and the center electrode, respectively, and the fourth power source is connected between the fifth electrode and the second electrode and the center electrode, respectively.
  • the wearable smart drug introduction system 220 of the present invention can be applied to the administration of four drugs, and the different drugs are placed in the first storage 223, the third storage 224, the fourth storage 225, and the fifth storage 226. Simultaneously applied between the electrodes of the first repository 223, the third repository 224, the fourth repository 225, and the fifth repository 226 by the first power source and the electrodes of the second repository 222 and the central repository 227 Transdermal administration of the medicament; or by a plurality of power sources respectively applied between the first reservoir 223 and the electrodes of the second reservoir 222 and the central repository 227, the third reservoir 224 and the second reservoir 222 and the center Between the electrodes of the reservoir 227, between the fourth reservoir 225 and the electrodes of the second reservoir 222 and the central repository 227, and between the fifth reservoir 226 and the electrodes of the second reservoir 222 and the central repository 227 Transdermal administration of the four agents simultaneously or at different times can be achieved by the switches of the first power source, the second power source, the third
  • the invention has the following advantages: the invention can wear the smart drug introduction system, and the dose and the conduction time of the ionization agent can be accurately and accurately controlled; the dose of the skin contact drug of the invention diffusing through the skin is much lower than the present invention; The dose of iontophoresis through the skin minimizes or avoids the uncontrolled dose of the drug percutaneous conduction; in the present invention, multiple drugs can be stored in one reservoir or in multiple reservoirs, and can be passed through one or more power sources. It is delivered to the body at the same time or at different times; and multiple drugs are stored in multiple reservoirs to avoid reaction and mutual interference between the drugs; it is also possible to reduce the skin irritation without using a transdermal enhancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种可佩戴智能药物导入系统(100,210,220)，包括电源、药囊结构，储存库，和电极结构。所述可佩戴智能药物导入系统(100,210,220)可以将离子化药剂的剂量和传导的时间准确地和精确地控制，减少并避免药物经皮传导不可控的剂量。所述可佩戴智能药物导入系统(100,210,220)中多个药物可以在一个储存库或多个储存库内保存，通过一个或多个电源可以在同一时间或在不同的时间传导到体内；并且多个药物在多个储存库内保存可以避免药物之间的反应和相互干扰。

Description

可佩戴智能药物导入系统 技术领域
本发明涉及一种可佩戴智能药物导入系统。
背景技术
药物对不同的疾病提供治疗效果，通常必须在某个时间给药或某个时间模式给药或必须保持药物在某个浓度水平来达到治疗效果最佳。不幸的是病人通常没有按照要求间隔或时段服药。而且口服药物由于胃的高酸度环境或肝脏的首过效应影响，会导致部分或全部失效。
为了克服这些问题，药物可以通过皮肤给药。常见的不经肠道给药方法是用注射器或连续滴注注射不同剂量药物。对于长期治疗患者来说这些方法可能不合适，因为针扎的反复伤害和静脉滴注装置会限制病人的行动自由，也给病人带来痛苦。
一种更舒适的药物给药装置是通过表皮给药。在中国的中医领域，这种贴膏或膏药的应用及其广泛。用贴膏方式给药通常在一段时间（如一天到一周），在无需病人主动要求给药的情况下，提供持续剂量的给药。日常应用适合通过皮肤给药的药物有：尼古丁、激素和一些镇痛药（如芬太尼）以及其他药物剂型改变的药物，比如盐酸多奈哌齐，阿司匹林，布洛芬，利他林等。其应用包括，用于戒烟的尼古丁贴剂；通过连续向皮肤释放低水平的雌激素和孕激素用于避孕的贴膏。这种表皮给药装置便携、舒适且非常适合对针扎恐惧的病人。通过表皮给药的主要优点有：按设计释放速率提供持续剂量；避免了胃肠道和肝脏的首过效应对口服药物的影响；无创；无需患者介入给药，但患者也可随时给药或停药。然而其优点对于一些治疗药物也是其缺点：由于维持体内的持续恒定剂量，就导致机体或疾病的耐药性和抗药性；人体的一些生理功能或病理现象呈明显的昼夜节律，给药应根据药物的生物利用度、血药浓度、代谢与排泄等过程中的昼夜节律性变化，持续恒定剂量反而会影响疗效，和产生不良反应和副作用。
电离子渗疗法是一种通过外加的电场介质驱动下离子流扩散的物理过程，使可溶性的离子盐类药物在电流作用下进入身体，从而达到治疗目的。电离子渗疗法的装置最早始于1900年以前。1934年，一篇英国专利(410,009)描述一个电离子渗疗装置，制造形成包括：多个电极和可以通过经皮穿透的含有治疗成分或药物的原料，以及一个提供离子透入传输药物所需能量的蓄电池。该装置由于减少了给药对病人日常生活的影响而被接受，是早期电离子渗透给药的实现。最近，美国专利发表了电离子渗疗法的相关技术，表明这个方法用于药物传导有更新的兴趣，比如Anderson等人的专利U.S.Pat.No.7,844,327；Durand的专利U.S.Pat.No.7,945,320；Kananmura等人的专利U.S.Pat.No.8,386,030；Anderson的专利U.S.Pat.No.8,463,373；Dombdisclose的专利U.S.Pat.No.8,666,486等列举了电离子渗透装置和一些应用。
通常在离子电渗疗法装置中，至少用到两个电极，直接与皮肤接触，并且在使用时候使用透皮促进剂，对于皮肤损害很大。一个电极叫活性电极，通过电力作用于化学物质，化合物，药剂，或药物，使其传输或进入体内。另一个是反电极。两个电极与皮肤和电源一起，形成一个闭合的电压或电流回路。例如：一个药物离子是正电极性（正电荷离子），那么正电极（阳极）就是活性电极与反电极（阴极）之间形成一个闭合回路。如果药物离子是带有负电荷的，那么负电极是活性电极，而正电极是反电极。离子电渗疗法的最突出的优点在于对药物传导量和时间的控制。
发明内容
本发明要解决的技术问题，在于提供一种可佩戴智能药物导入系统，便于用户使用。
本发明方案之一是这样实现的：一种可佩戴智能药物导入系统，包括药囊结构及第一电源，所述药囊结构内设有第一储存库及第二储存库，所述第二储存库为环形，所述第一储存库设于所述第二储存库环形内，所述第一储存库内设有第一电极，所述第一储存库一侧面设有第一开口，所述第一开口处设有第一透释膜，所述第一储存库中充满凝胶状药液，所述第二储存库内设有第二电极，所述第二储存库一侧面设有第二开口，所述第二开口处设有第二透释膜，所述第二储存库中充满凝胶状电解液，所述第一电源的正负极分别连接所述第一电极及第二电极。
进一步地，所述第一开口与所述第一电极相对，所述第二开口与所述第二电极相对。
进一步地，所述第一储存库与所述第二储存库的间距大于10mm。
进一步地，所述第一开口处设有第一透释膜，所述第二开口处设有第二透释膜。
进一步地，所述凝胶状药物可拆卸设于所述第一储存库内，所述凝胶状电解液可拆卸设于所述第二储存库内。
进一步地，还包括至少一个第三储存库，每个所述第三储存室设于所述第一储存库环形内，每个所述第三储存库内设有第三电极，每个所述第三储存库一侧面设有第三开口，所述第三开口处设有第三透释膜，每个所述第三储存库中充满凝胶状药液，所述第一电源连接至每个所述第三电极。
进一步地，所述第三开口与所述第三电极相对。
本发明方案之二是这样实现的：一种可佩戴智能药物导入系统，包括药囊结构及第一电源，所述药囊结构内设有第一储存库、第二储存库和一个中心储存库。所述第二储存库为环形，所述第一储存库也为环形，设于所述第二储存库环形内和中心储存库之间。所述第一储存库内设有第一电极，所述第一储存库一侧面设有第一开口，所述第一储存库中充满凝胶状药液；所述第二储存库内设有第二电极，所述第二储存库一侧面设有第二开口，所述第二储存库中充满凝胶状电解液，所述中心储存库内设有中心电极，所述中心储存库一侧面设有中心开口，所述中心储存库中充满凝胶状电解液，所述第一电源的正负极分别连接所述第一电极与第二电极和中心电极之间。
进一步地，所述第一开口处设有第一透释膜，所述第二开口处设有第二透释膜，所述中心开口处设有中心透释膜。
进一步地，所述第一储存库可分为至少一个第三储存库、所述第三储存库内设有第三电极，所述第三储存库一侧面设有第三开口，所述第三开口处设有第三透释膜，所述第三储存库中充满凝胶状药液。
本发明具有如下优点：本发明可佩戴智能药物导入系统，可以将离子化药剂的剂量和传导的时间可以准确地和精确地控制;本发明与皮肤接触药物的扩散穿过皮肤的剂量远低于离子电渗穿过皮肤的剂量，使药物经皮传导不可控的剂量最小化或得到避免;本发明中多个药物可以在一个储存库或多个储存库内保存，通过一个或多个电源可以在同一时间或在不同的时间传导到体内；并且多个药物在多个储存库内保存可以避免药物之间的反应和相互干扰；还可以不需要采用透皮促进剂，对皮肤刺激减小。
附图说明
下面参照附图结合实施例对本发明作进一步的说明。
图1为本发明实施例一的结构示意图。
图2为本发明实施例一的剖视图。
图3为本发明实施例二的结构示意图。
图4为本发明实施例三的结构示意图。
具体实施方式
本发明可佩戴智能药物导入系统，包括药囊结构及第一电源，所述药囊结构内设有第一储存库及第二储存库，所述第二储存库为环形，所述第一储存库设于所述第二储存库环形内，所述第一储存库内设有第一电极，所述第一储存库一侧面设有第一开口，所述第一开口处设有第一透释膜，所述第一储存库中充满凝胶状药液，所述第二储存库内设有第二电极，所述第二储存库一侧面设有第二开口，所述第二开口处设有第二透释膜，所述第二储存库中充满凝胶状电解液，所述第一电源的正负极分别连接所述第一电极及第二电极，所述第一开口与所述第一电极相对，所述第二开口与所述第二电极相对，所述第一储存库与所述第二储存库的间距大于10mm，所述凝胶状药物可拆卸设于所述第一储存库内，所述凝胶状电解液可拆卸设于所述第二储存库内。
本发明还包括至少一个第三储存库，每个所述第三储存室设于所述第一储存库环形内，每个所述第三储存库内设有第三电极，每个所述第三储存库一侧面设有第三开口，所述第三开口处设有第三透释膜，每个所述第三储存库中充满凝胶状药液，所述第一电源连接至每个所述第三电极，所述第三开口与所述第三电极相对。
本发明的另一实施例包括至少第一储存库、第二储存库和一个中心储存库。所述第二储存库为环形，所述第一储存库也为环形，设于所述第二储存库环形内和中心储存库之间。所述第一储存库内设有第一电极，所述第一储存库一侧面设有第一开口，所述第一开口处设有第一透释膜，所述第一储存库中充满凝胶状药液；所述第二储存库内设有第二电极，所述第二储存库一侧面设有第二开口，所述第二开口处设有第二透释膜，所述第二储存库中充满凝胶状电解液；所述中心储存库内设有中心电极，所述中心储存库一侧面设有中心开口，所述中心开口处设有中心透释膜，所述中心储存库中充满凝胶状电解液，所述第一电源的正负极分别连接所述第一电极与第二电极和中心电极之间。
本发明实施例所述透释膜，药物离子通过上述的透释膜传导到皮肤，或者也可以称为通透膜，有一定孔径的均匀小孔组成薄膜结构。
为了更加详细的说明本发明，结合附图进一步的进行说明，如下所示：
如图1和图2展示了根据本发明的第一种实施例。本发明可佩戴智能药物导入系统100由一个圆形药囊结构101和第一电源（图中未标出）组成，在圆形药囊结构101中有一个圆形的第一储存库103和一个环形第二储存库102组成，所述第一储存库103内设有一第一电极106，第二储存库102内设有一第二电极105，如图2所示，第一电极106及第二电极105被安装在各储存库的顶壁中，所述第一储存库103的底部设有第一透释膜（图中未示），所述第二储存库102的底部设有第二透释膜（图中未示），第一电源可以被用于第一储存库103中的第一电极106和第二储存库102中的第二电极105。
药囊结构101部分可以用合成材料或者硅橡胶制得。本发明可佩戴智能药物导入系统100的尺寸是直径75mm，高6mm，但是其他尺寸也可以用。第一储存库103的直径20mm，高3mm。第二储存库102可以是内径40mm，外径45mm，高3mm的圆环状，其他尺寸也可以使用。这第二储存库102及第一储存库103的底部面积尽可能保证相同，第二储存库102和第一储存库103之间的距离L应该保证大于10mm，以保证电流能均匀的分散在皮肤上。
对于正电离子化的药剂，可将凝胶状的离子化药剂储存在第一储存库103中。而在第二储存库102中的凝胶可以是仅包含电解离子的凝胶。第一电源的正电源端就施加于第一储存库103中的第一电极106上，第一电源的负电源端施加于在第二储存库102的第二电极105，当第一电源启动后，在第一储存库103中正电离子化药剂在库伦力作用下就从第一储存库103经过第一透释膜被传送到其下方的皮肤上，透过皮肤传到体内。同时，通过控制第一电源的输出电流或电压的强度就可以按剂量将离子化药剂传到体内。
正电离子化的药剂和负电离子化的药剂可与凝胶基质混合形成凝胶状药液，分别储存在第一储存库103或第二储存库102中。参考的凝胶基质可以是有机凝胶，水凝胶，此外，羟乙基纤维素可以与凝胶基质混合，但其它凝胶基质也可以使用。
在药囊结构装置本体100的设计上，对应第一储存库102和第二储存库103的位置可以是空腔结构。凝胶状电解液以及凝胶状药物可以制作成以第一储存库102和第二储存库103其对应空腔结构的大小和形状，凝胶状电解液和凝胶状药物就可以放入其中。这样，凝胶状电解液和凝胶状药物可以替换，而药囊结构装置本体100可以做到可佩戴智能药物导入装置一体。
如图3所示，为本发明的第二种具体实施例，本发明可佩戴智能药物导入系统210包含有药囊结构装置211、第一电源（图中未标出）、第一储存库213、第三储存库214、第四储存库215和第五储存库216，以及一个圆环形的第二储存库212，第一储存库213顶部设有第一电极（图中未示），第一储存库213的底部设有第一开口（图中未示），所述第一开口处设有第一透释膜（图中未示）；第三储存库214顶部设有第三电极（图中未示），第三储存库214的底部设有第三开口（图中未示），所述第三开口处设有第三透释膜（图中未示）；第四储存库215顶部设有第四电极（图中未示），第四储存库215的底部设有第四开口（图中未示），所述第四开口处设有第四透释膜（图中未示）；第五储存库216顶部设有第五电极（图中未示），第五储存库216的底部设有第五开口（图中未示），所述第五开口处设有第五透释膜（图中未示）；第二储存库212顶部设有第二电极（图中未示），第二储存库212的底部设有第二开口（图中未示），所述第二开口处设有第二透释膜（图中未示）；本发明可佩戴智能药物导入系统210可适用于四种药剂的给药，将不同的药剂放入第一储存库213、第三储存库214、第四储存库215和第五储存库216，通过第一电源施加于第一储存库213、第三储存库214、第四储存库215和第五储存库216的电极与第二储存库212的电极之间，实现同时四种药剂的透皮给药；或者通过多个电源分别施加于第一储存库213与第二储存库212的电极之间、第三储存库214与第二储存库212的电极之间、第四储存库215与第二储存库212的电极之间，和第五储存库216与第二储存库212的电极之间，实现不同时四种药剂的透皮给药。
如图4所示，本发明的第三种具体实施例，本发明可佩戴智能药物导入系统220，包括第一电源（图中未标出）、第一储存库223、第三储存库224、第四储存库225和第五储存库226，以及一个圆环形的第二储存库222和一个中心储存库227，第一储存库223顶部设有第一电极（图中未示），第一储存库223的底部设有第一开口（图中未示），所述第一开口处设有第一透释膜（图中未示）；第三储存库224顶部设有第三电极（图中未示），第三储存库224的底部设有第三开口（图中未示），所述第三开口处设有第三透释膜（图中未示）；第四储存库225顶部设有第四电极（图中未示），第四储存库225的底部设有第四开口（图中未示），所述第四开口处设有第四透释膜（图中未示）；第五储存库226顶部设有第五电极（图中未示），第五储存库226的底部设有第五开口（图中未示），所述第五开口处设有第五透释膜（图中未示）；第二储存库222顶部设有第二电极（图中未示），第二储存库222的底部设有第二开口（图中未示），所述第二开口处设有第二透释膜（图中未示）；为了使电流更均匀的分布于可佩戴智能药物导入系统下的区域内，可佩戴智能药物导入系统220还包括一中心储存库227，所述中心储存库227的顶部设有中心电极（图中未示），所述中心储存库227的底部设有第六开口（图中未示），所述第六开口处设有第六透释膜（图中未示）。在这个实施方案中四种药剂可以分别置于四个储存库223，224，225和226中。
第二储存库222的第三电极和中心储存库227的中心电极相连。通过第一电源施加于第一储存库223、第三储存库224、第四储存库225和第五储存库226的电极与第二储存库222和中心储存库227的电极之间，实现同时四种药剂的透皮给药；或者通过多个电源分别施加于第一储存库223与第二储存库222和中心储存库227的电极之间、第三储存库224与第二储存库222和中心储存库227的电极之间、第四储存库225与第二储存库222和中心储存库227的电极之间，和第五储存库226与第二储存库222和中心储存库227的电极之间，实现不同时四种药剂的透皮给药。
进一步本发明的第三种具体实施例还可包括第二电源（图中未示）、第三电源（图中未示）及第四电源（图中未示），第一电源分别连接第一电极与第二电极和中心电极之间，也即第一储存库223与第二储存库222和中心储存库227的电极之间，第二电源分别连接第三电极与第二电极和中心电极之间，第三电源分别连接第四电极与第二电极和中心电极之间，第四电源分别连接第五电极与第二电极和中心电极之间。
本发明可佩戴智能药物导入系统220可适用于四种药剂的给药，将不同的药剂放入第一储存库223、第三储存库224、第四储存库225和第五储存库226。通过第一电源施加于第一储存库223、第三储存库224、第四储存库225和第五储存库226的电极与第二储存库222和中心储存库227的电极之间，实现同时四种药剂的透皮给药；或者通过多个电源分别施加于第一储存库223与第二储存库222和中心储存库227的电极之间、第三储存库224与第二储存库222和中心储存库227的电极之间、第四储存库225与第二储存库222和中心储存库227的电极之间，和第五储存库226与第二储存库222和中心储存库227的电极之间，通过第一电源、第二电源、第三电源及第四电源的开关即可实现四种药剂同时或不同时的透皮给药。
本发明具有如下优点：本发明可佩戴智能药物导入系统，可以将离子化药剂的剂量和传导的时间可以准确地和精确地控制;本发明与皮肤接触药物的扩散穿过皮肤的剂量远低于离子电渗穿过皮肤的剂量，使药物经皮传导不可控的剂量最小化或得到避免;本发明中多个药物可以在一个储存库或多个储存库内保存，通过一个或多个电源可以在同一时间或在不同的时间传导到体内；并且多个药物在多个储存库内保存可以避免药物之间的反应和相互干扰；还可以不需要采用透皮促进剂，对皮肤刺激减小。
虽然以上描述了本发明的具体实施方式，但是熟悉本技术领域的技术人员应当理解，我们所描述的具体的实施例只是说明性的，而不是用于对本发明的范围的限定，熟悉本领域的技术人员在依照本发明的精神所作的等效的修饰以及变化，都应当涵盖在本发明的权利要求所保护的范围内。

Claims (10)

1、一种可佩戴智能药物导入系统，其特征在于：包括药囊结构及第一电源，所述药囊结构内设有第一储存库及第二储存库，所述第二储存库为环形，所述第一储存库设于所述第二储存库环形内，所述第一储存库内设有第一电极，所述第一储存库一侧面设有第一开口，所述第一储存库中充满凝胶状药液，所述第二储存库内设有第二电极，所述第二储存库一侧面设有第二开口，所述第二储存库中充满凝胶状电解液，所述第一电源的正负极分别连接所述第一电极及第二电极。
2、根据权利要求1所述的可佩戴智能药物导入系统，其特征在于：所述第一开口与所述第一电极相对，所述第二开口与所述第二电极相对。
3、根据权利要求1所述的可佩戴智能药物导入系统，其特征在于：所述第一开口处设有第一透释膜，所述第二开口处设有第二透释膜。
4、根据权利要求1所述的可佩戴智能药物导入系统，其特征在于：所述第一储存库与所述第二储存库的间距大于10mm。
5、根据权利要求1所述的可佩戴智能药物导入装置，其特征在于：所述凝胶状药物可拆卸设于所述第一储存库内，所述凝胶状电解液可拆卸设于所述第二储存库内。
6、根据权利要求1所述的可佩戴智能药物导入系统，其特征在于：还包括至少一个第三储存库，每个所述第三储存室设于所述第二储存库环形内，每个所述第三储存库内设有第三电极，每个所述第三储存库一侧面设有第三开口，所述第三开口处设有第三透释膜，每个所述第三储存库中充满凝胶状药液，所述第一电源连接至每个所述第三电极。
7、根据权利要求6所述的可佩戴智能药物导入系统，其特征在于：所述第三开口与所述第三电极相对。
8、一种可佩戴智能药物导入系统，其特征在于：包括药囊结构及第一电源，所述药囊结构内设有第一储存库、第二储存库和一个中心储存库。所述第二储存库为环形，所述第一储存库也为环形，设于所述第二储存库环形内和中心储存库之间。所述第一储存库内设有第一电极，所述第一储存库一侧面设有第一开口，所述第一储存库中充满凝胶状药液；所述第二储存库内设有第二电极，所述第二储存库一侧面设有第二开口，所述第二储存库中充满凝胶状电解液，所述中心储存库内设有中心电极，所述中心储存库一侧面设有中心开口，所述中心储存库中充满凝胶状电解液，所述第一电源的正负极分别连接所述第一电极与第二电极和中心电极之间。
9、根据权利要求8所述的可佩戴智能药物导入系统，其特征在于：所述第一开口处设有第一透释膜，所述第二开口处设有第二透释膜，所述中心开口处设有中心透释膜
10、根据权利要求8所述的可佩戴智能药物导入系统，其特征在于：所述第一储存库可分为至少一个第三储存库、所述第三储存库内设有第三电极，所述第三储存库一侧面设有第三开口，所述第三开口处设有第三透释膜，所述第三储存库中充满凝胶状药液。
PCT/CN2015/092546 2014-10-31 2015-10-22 可佩戴智能药物导入系统 WO2016066050A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/312,182 US20170072184A1 (en) 2014-10-31 2015-10-22 Wearable smart drug-delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410600426.0 2014-10-31
CN201410600426.0A CN104353183B (zh) 2014-10-31 2014-10-31 电解液位置固定的可佩戴智能药物导入结构

Publications (1)

Publication Number Publication Date
WO2016066050A1 true WO2016066050A1 (zh) 2016-05-06

Family

ID=52520548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/092546 WO2016066050A1 (zh) 2014-10-31 2015-10-22 可佩戴智能药物导入系统

Country Status (3)

Country Link
US (1) US20170072184A1 (zh)
CN (1) CN104353183B (zh)
WO (1) WO2016066050A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104353183B (zh) * 2014-10-31 2016-12-07 厦门微科格瑞生物科技有限公司 电解液位置固定的可佩戴智能药物导入结构
CN111135454A (zh) * 2019-11-20 2020-05-12 浙江省北大信息技术高等研究院 一种经皮给药贴片
CN111529921B (zh) * 2020-04-10 2022-03-29 常州华佳医疗器械有限公司 一种载药托盘

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000237327A (ja) * 1999-02-19 2000-09-05 R & R Ventures Kk イオントフォレーゼによるイオン性薬剤の投与法
US20070093742A1 (en) * 2005-10-24 2007-04-26 Higuchi John W Intraocular iontophoretic device and associated methods
CN101115523A (zh) * 2005-02-03 2008-01-30 透皮技术株式会社 离子电渗疗装置
CN101277737A (zh) * 2005-09-30 2008-10-01 Tti优而美株式会社 将多种活性剂输送至生物界面的离子电渗装置
CN104353183A (zh) * 2014-10-31 2015-02-18 厦门微科格瑞生物科技有限公司 电解液位置固定的可佩戴智能药物导入结构
CN204246685U (zh) * 2014-10-31 2015-04-08 厦门微科格瑞生物科技有限公司 电解液位置固定的可佩戴智能药物导入结构

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5203768A (en) * 1991-07-24 1993-04-20 Alza Corporation Transdermal delivery device
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
US7662176B2 (en) * 2004-02-19 2010-02-16 Vomaris Innovations, Inc. Footwear apparatus and methods of manufacture and use
US8755880B2 (en) * 2005-10-24 2014-06-17 Aciont, Inc. Intraocular iontophoretic device and associated methods
JP5463136B2 (ja) * 2009-12-22 2014-04-09 帝國製薬株式会社 イオントフォレーシス療法に用いる電極装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000237327A (ja) * 1999-02-19 2000-09-05 R & R Ventures Kk イオントフォレーゼによるイオン性薬剤の投与法
CN101115523A (zh) * 2005-02-03 2008-01-30 透皮技术株式会社 离子电渗疗装置
CN101277737A (zh) * 2005-09-30 2008-10-01 Tti优而美株式会社 将多种活性剂输送至生物界面的离子电渗装置
US20070093742A1 (en) * 2005-10-24 2007-04-26 Higuchi John W Intraocular iontophoretic device and associated methods
CN104353183A (zh) * 2014-10-31 2015-02-18 厦门微科格瑞生物科技有限公司 电解液位置固定的可佩戴智能药物导入结构
CN204246685U (zh) * 2014-10-31 2015-04-08 厦门微科格瑞生物科技有限公司 电解液位置固定的可佩戴智能药物导入结构

Also Published As

Publication number Publication date
CN104353183A (zh) 2015-02-18
US20170072184A1 (en) 2017-03-16
CN104353183B (zh) 2016-12-07

Similar Documents

Publication Publication Date Title
KR950008027B1 (ko) 전리요법 장치 및 방법 및 단위용량
KR100994631B1 (ko) 전리요법을 이용해 그라니세트론을 포함한 치료제를투약하기 위한 경피형 시스템
US6564093B1 (en) Transdermal active drug delivery system and method
US4752285A (en) Methods and apparatus for iontophoresis application of medicaments
KR950008026B1 (ko) 피부를 통한 의약 투여장치
JP2636290B2 (ja) イオン導入ドラグデリバリー装置
BRPI0616771A2 (pt) dispositivo de iontoforese para liberar múltiplos agentes ativos para interfaces biológicas
JPH07504110A (ja) ユーザ作動型のイオン導入式装置
JP2002541935A (ja) 内部センサを有する電気的な移動による送出装置系
BRPI0616487A2 (pt) aparato e método de iontoforese para liberação sistêmica de agentes ativos
ES2331981T3 (es) Dispositivo de administracion transdermica por electrotransporte de fentanilo y sufentanilo.
US11511095B2 (en) Portable transdermal administration patch apparatus and preparation method thereof
WO2016066118A1 (zh) 可佩戴智能药物导入装置
US20090214625A1 (en) Drug delivery patch
WO2016066050A1 (zh) 可佩戴智能药物导入系统
US9492661B2 (en) Device and methods for enhanced multi-delivery of biologically active substances into an organism and to prevent local irritation
US6375990B1 (en) Method and devices for transdermal delivery of lithium
JPH05504272A (ja) イオン浸透療法装置および速度調整膜を用いた方法
EP0586666B2 (en) User activated iontophoretic device
CN204246683U (zh) 可佩戴智能药物导入系统
CN204246685U (zh) 电解液位置固定的可佩戴智能药物导入结构
CN204246684U (zh) 一种可佩戴智能药物导入装置
CN104353182B (zh) 一种可佩戴智能药物导入装置
Li et al. Drug delivery using electrophoresis
WO2009051994A2 (en) Electrotransport of lisuride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15854414

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15312182

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15854414

Country of ref document: EP

Kind code of ref document: A1